GENE ONLINE|News &
Fennec Submits Hearing Loss Drug for Third Time After Prior FDA Approval Rejections
Fennec’s PEDMARK is designed to prevent ototoxicity in patients aged one month to 18 years old using a novel formulation of sodium thiosulfate. Through clinical trials, Fennec says that PEDMARK is most effectively administered in an intravenous bolus dose within six hours of chemotherapy treatment.
Despite receiving numerous regulatory milestones and praise after successful clinical trials, Fennec struggles to receive FDA approval for its seemingly promising drug.
Despite receiving numerous regulatory milestones and praise after successful clinical trials, Fennec struggles to receive FDA approval for its seemingly promising drug.
It's free! Log in now to read
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
